Agalsidase beta vs isaralgagene civaparvovec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Fabry Disease
Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline
Agalsidase beta · Fabrazyme
Marketed by Sanofi
NCT00837824 · Phase 2 · terminated
This study was randomized but not blinded, had no placebo control, and was terminated early after enrolling only a sixth of its planned patients; with just one clinical event recorded across both dose groups, it could not produce a meaningful comparison of Fabrazyme's effect on disease progression.
Reported efficacy
Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium (Baseline, Week 52, Week 156 and Week 260): Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). (unclear)
Result source: NCT00701415
isaralgagene civaparvovec
Developed by PTC Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Fabry Disease
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
isaralgagene civaparvovec: registry results are on file for Fabry Disease, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Agalsidase beta
Available safety results
Agalsidase beta
| Dropout rate | 0%3mg/kg Every 2 Weeks NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 show 1 more result0%1mg/kg Every 2 Weeks NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 |
|---|---|
| Discontinued due to AEs | —3mg/kg Every 2 Weeks NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 show 1 more result—1mg/kg Every 2 Weeks NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 |
| Serious AEs | 11.1%3mg/kg Every 2 Weeks NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 show 1 more result36.4%1mg/kg Every 2 Weeks NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 |
| Most frequent reported AEs | 3mg/kg Every 2 Weeks oedema peripheral 33.3% headache 22.2% muscle spasms 22.2% NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 show 1 more result1mg/kg Every 2 Weeks abdominal pain 18.2% pyrexia 18.2% transient ischaemic attack 18.2% NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Agalsidase beta's landscape · isaralgagene civaparvovec's landscape